Paychex (PAYX) Tops Q4 EPS by 1c, Slight Beat on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
Paychex (PAYX) PT Lowered to $60 at JPMorgan Following 4Q
June 29, 2017 9:55 AM EDTJPMorgan lowered its price target on Paychex (NASDAQ: PAYX) to $60.00 (from $62.00) while maintaining a Neutral rating following the company's 4Q earnings report and guidance. 4Q revenue of $799M was reported in-line with the Street's $798M estimates. EPS of $0.54 was one cent above the Street's... More
Paychex (PAYX) PT Lowered to $55 at Morgan Stanley Following 4Q
June 29, 2017 9:39 AM EDTMorgan Stanley lowered its price target on Paychex (NASDAQ: PAYX) to $55.00 (from $56.00) while maintaining a Underweight rating following the company's 4Q earnings report. 4Q revenue was in line at $799mn vs. the consensus estimate of 798mn. EPS at $0.54 was also in line with... More
Paychex (PAYX) PT Lowered to $60 at Baird on Q4 Report; 'Sub PAR Metrics, Revenue Growth to Slow but Profitability Resilient'
June 29, 2017 9:22 AM EDTBaird lowered its price target on Paychex (NASDAQ: PAYX) to $60.00 (from $63.00) while maintaining a Neutral rating, following the company's fourth quarter earnings report.
Analyst Mark Marcon notes the company delivered fourth quarter earnings per share and revenue results above consensus projections, despite key metrics... More

